Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
An update from Portage Biotech Inc ( (PRTG) ) is now available.
Portage Biotech Inc. has entered into a Letter of Intent with Immunova LLC to negotiate the sale of its subsidiary, iOx Therapeutics, Ltd, which focuses on developing liposomal iNKT agonists. This potential acquisition aligns with both companies’ strategic goals to enhance their pipelines and bring innovative therapies to market, potentially impacting shareholders and the biotech industry positively if concluded successfully.
More about Portage Biotech Inc
Portage Biotech Inc. is a clinical-stage immuno-oncology company focused on developing a portfolio of novel biologics aimed at enhancing the immune system’s ability to combat cancer. The company emphasizes discovering therapies with unique mechanisms to meet unmet patient needs. Meanwhile, Immunova LLC is a Connecticut-based biotechnology firm specializing in lipid-based drugs and immune-modulating therapies, committed to advancing innovative treatments for cancer and other diseases.
YTD Price Performance: -91.07%
Average Trading Volume: 924,304
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $3.64M
For a thorough assessment of PRTG stock, go to TipRanks’ Stock Analysis page.
